Jenn Logue, MD

Dr. Logue received her MD from Boston University School of Medicine. She completed an Internal Medicine Residency at Wake Forest School of Medicine followed by a Hematology/Oncology Fellowship at Moffitt Cancer Center/University of South Florida. Dr. Logue most recently completed a Blood and Marrow Transplant and Cellular Immunotherapy Fellowship at Moffitt Cancer Center. Dr. Logue’s specialty is Malignant Hematology with a focus on Blood and Marrow Transplant and Cellular Immunotherapy. Her clinical concentration is lymphoma and multiple myeloma, specifically with transplant and cellular therapies. Dr. Logue’s research focus is treatment with chimeric antigen receptor (CAR) T-cell therapies in lymphoma and myeloma, especially anti-CD19 CAR T-cell therapy and anti-BCMA CAR T-cell therapy. Her research interest is the assessment of treatment toxicities, late effects, and patient-reported outcomes within the realm of transplant and cell therapy.

Education & Training

Fellowship:

• University of South Florida/Moffitt Cancer Center - Hematology/Oncology
• Moffitt Cancer Center - Cellular Immunotherapy

Residency:

• Wake Forest School of Medicine - Internal Medicine

Medical School:

• Boston University School of Medicine - MD

• Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul.16(1):88. Pubmedid: 37525244. Pmcid: PMC10391746.
• Hoogland AI, Barata A, Logue J, Kommalapati A, Hyland KA, Nelson AM, Eisel SL, Small BJ, James BW, Christy SM, Bulls HW, Booth-Jones M, Jayani RV, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Jun.28(6):305.e1-305.e9. Pubmedid: 35378330. Pmcid: PMC9197947.
• Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mokhtari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim HSL. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Transplant Cell Ther. 2022 Jul.28(7):401.e1-401.e7. Pubmedid: 35580732. Pmcid: PMC9339228.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Logue JM, Chavez JC. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure. CURR TREAT OPTION ON. 2021 Oct.22(12):112. Pubmedid: 34697650.
• Barata A, Hoogland AI, Hyland KA, Otto AK, Kommalapati A, Jayani RV, Irizarry-Arroyo N, Collier A, Rodriguez Y, Welniak TL, Booth-Jones M, Logue J, Small BJ, Jain MD, Reblin M, Locke FL, Jim HSL. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Psychooncology. 2021 Aug.30(8):1294-1301. Pubmedid: 33739548. Pmcid: PMC9828891.
• Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
• Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J. CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. Sci Rep. 2019 Oct.9(1):14385. Pubmedid: 31591443. Pmcid: PMC6779906.
• Shah BA, Qureshi MM, Logue JM, Cooley TP, Zaner KS, Jalisi S, Truong MT. Assessing cumulative acute toxicity of chemoradiotherapy in head and neck cancer with or without induction chemotherapy. Am J Otolaryngol. 2018 May.38(4):456-461. Pubmedid: 28427799.
• Logue JM, Kiani B, Bitting RL. Pazopanib and Statin-Induced Rhabdomyolysis. Case Rep Oncol. 2017 Oct.10(3):954-957. Pubmedid: 29279698. Pmcid: PMC5731169.
• Ahn Y, Sims C, Logue JM, Weatherbee SD, Krumlauf R. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling. Development. 2013 Feb.140(3):583-593. Pubmedid: 23293290. Pmcid: PMC6514302.